HYDERABAD: Lower than six months after it rolled out wearable migraine administration gadget Nerivio within the Indian market, Dr Reddy’s Laboratories has now rolled out the drug-free, non-invasive gadget within the European market.
The corporate has launched Nerivio in Germany to start out with by its step-down subsidiary betapharm, marking its foray into digital therapeutics in Europe.
It plans to additionally introduce Nerivio in Spain and the UK within the coming months, Dr Reddy’s mentioned on Wednesday.
The Hyderabad-based pharma main has an unique settlement with digital therapeutics participant Theranica for advertising and distributing Nerivio in a number of markets.
The prescription-based gadget, which could be worn on the higher arm, is supposed for treating adults and adolescents aged 12 years and above affected by migraine with or with out aura.
The gadget makes use of the Distant Electrical Neuromodulation (REN) mechanism to activate conditioned ache modulation by stimulating nerve endings. This initiates a pure pain-relieving course of within the brainstem, inflicting a worldwide impact of ache inhibition that impacts the unique supply of migraine ache within the head.
Every gadget has in-built 18 remedy periods of 45 minutes every and can be utilized inside 60 minutes of onset of headache for acute remedy or each alternate day for prevention of migraine.
Dr Reddy’s CEO for branded markets (India & rising markets) MV Ramana mentioned the gadget has acquired optimistic suggestions from neurologists in India and has proven promising leads to offering reduction to migraine sufferers, serving to handle their unmet medical wants and lowering their capsule burden.
The gadget is permitted by america Meals & Drug Administration (USFDA) and holds the CE-mark certification in Europe.
It has been showcased at occasions such because the DGN Kongress and the European Headache Congress in 2023, and also will be offered on the Neurological Affiliation of South Africa annual congress on April 17, this yr.
Nerivio will even be showcased on the Worldwide Headache Society 2024 iHEAD assembly in Berlin, Germany, in Could 2024.
The corporate has launched Nerivio in Germany to start out with by its step-down subsidiary betapharm, marking its foray into digital therapeutics in Europe.
It plans to additionally introduce Nerivio in Spain and the UK within the coming months, Dr Reddy’s mentioned on Wednesday.
The Hyderabad-based pharma main has an unique settlement with digital therapeutics participant Theranica for advertising and distributing Nerivio in a number of markets.
The prescription-based gadget, which could be worn on the higher arm, is supposed for treating adults and adolescents aged 12 years and above affected by migraine with or with out aura.
The gadget makes use of the Distant Electrical Neuromodulation (REN) mechanism to activate conditioned ache modulation by stimulating nerve endings. This initiates a pure pain-relieving course of within the brainstem, inflicting a worldwide impact of ache inhibition that impacts the unique supply of migraine ache within the head.
Every gadget has in-built 18 remedy periods of 45 minutes every and can be utilized inside 60 minutes of onset of headache for acute remedy or each alternate day for prevention of migraine.
Dr Reddy’s CEO for branded markets (India & rising markets) MV Ramana mentioned the gadget has acquired optimistic suggestions from neurologists in India and has proven promising leads to offering reduction to migraine sufferers, serving to handle their unmet medical wants and lowering their capsule burden.
The gadget is permitted by america Meals & Drug Administration (USFDA) and holds the CE-mark certification in Europe.
It has been showcased at occasions such because the DGN Kongress and the European Headache Congress in 2023, and also will be offered on the Neurological Affiliation of South Africa annual congress on April 17, this yr.
Nerivio will even be showcased on the Worldwide Headache Society 2024 iHEAD assembly in Berlin, Germany, in Could 2024.
